secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001193125-26-102170
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya reports FY2025 net loss of $90.6M; cash runway into H2 2027
------------------------------------------------------------------

- Net loss $90.6M ($0.59/share) for FY2025 vs $111.1M ($1.31) in FY2024; Q4 net loss $20.2M.
- Cash, equivalents and investments $100.5M at Dec 31, 2025; December offering net $55.8M plus Alnylam upfront extend runway into H2 2027.
- TN-201 (HCM) and TN-401 (ARVC) gene therapies: interim data presented; enrollment resumed; plans for regulatory alignment in 2026.
- Entered multi-target collaboration with Alnylam: $10M upfront, up to $1.1B milestones; Alnylam handles development and commercialization.
- TN-301 (HDAC6i) preclinical DMD data: improved grip strength to wild-type levels at 3 mg/kg, outperforming givinostat.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000119312526102170/0001193125-26-102170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000119312526102170/tnya-20260311.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-102170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer